152 related articles for article (PubMed ID: 23021993)
1. Development of potent macrocyclic inhibitors of genotype 3a HCV NS3/4A protease.
Rudd MT; McCauley JA; Romano JJ; Butcher JW; Bush K; McIntyre CJ; Nguyen KT; Gilbert KF; Lyle TA; Holloway MK; Wan BL; Vacca JP; Summa V; Harper S; Rowley M; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; Liverton NJ
Bioorg Med Chem Lett; 2012 Dec; 22(23):7201-6. PubMed ID: 23021993
[TBL] [Abstract][Full Text] [Related]
2. Development of macrocyclic inhibitors of HCV NS3/4A protease with cyclic constrained P2-P4 linkers.
Rudd MT; McIntyre CJ; Romano JJ; Butcher JW; Holloway MK; Bush K; Nguyen KT; Gilbert KF; Lyle TA; Liverton NJ; Wan BL; Summa V; Harper S; Rowley M; Vacca JP; Carroll SS; Burlein C; DiMuzio JM; Gates A; Graham DJ; Huang Q; Ludmerer SW; McClain S; McHale C; Stahlhut M; Fandozzi C; Taylor A; Trainor N; Olsen DB; McCauley JA
Bioorg Med Chem Lett; 2012 Dec; 22(23):7207-13. PubMed ID: 23084906
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
[TBL] [Abstract][Full Text] [Related]
4. Bismacrocyclic inhibitors of hepatitis C NS3/4a protease.
McCauley JA; Rudd MT; Nguyen KT; McIntyre CJ; Romano JJ; Bush KJ; Varga SL; Ross CW; Carroll SS; DiMuzio J; Stahlhut MW; Olsen DB; Lyle TA; Vacca JP; Liverton NJ
Angew Chem Int Ed Engl; 2008; 47(47):9104-7. PubMed ID: 18925594
[No Abstract] [Full Text] [Related]
5. Novel macrocyclic inhibitors of hepatitis C NS3/4A protease featuring a 2-amino-1,3-thiazole as a P4 carbamate replacement.
Di Francesco ME; Dessole G; Nizi E; Pace P; Koch U; Fiore F; Pesci S; Di Muzio J; Monteagudo E; Rowley M; Summa V
J Med Chem; 2009 Nov; 52(22):7014-28. PubMed ID: 19856919
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of potent inhibitors of the Hepatitis C virus NS3/4A protease: exploration of P2 quinazoline substituents.
Nilsson M; Belfrage AK; Lindström S; Wähling H; Lindquist C; Ayesa S; Kahnberg P; Pelcman M; Benkestock K; Agback T; Vrang L; Terelius Y; Wikström K; Hamelink E; Rydergård C; Edlund M; Eneroth A; Raboisson P; Lin TI; de Kock H; Wigerinck P; Simmen K; Samuelsson B; Rosenquist S
Bioorg Med Chem Lett; 2010 Jul; 20(14):4004-11. PubMed ID: 20541405
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease.
Liverton NJ; Holloway MK; McCauley JA; Rudd MT; Butcher JW; Carroll SS; DiMuzio J; Fandozzi C; Gilbert KF; Mao SS; McIntyre CJ; Nguyen KT; Romano JJ; Stahlhut M; Wan BL; Olsen DB; Vacca JP
J Am Chem Soc; 2008 Apr; 130(14):4607-9. PubMed ID: 18338894
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of new acylsulfamoyl benzoxaboroles as potent inhibitors of HCV NS3 protease.
Li X; Zhang YK; Liu Y; Zhang S; Ding CZ; Zhou Y; Plattner JJ; Baker SJ; Liu L; Bu W; Kazmierski WM; Wright LL; Smith GK; Jarvest RL; Duan M; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7493-7. PubMed ID: 21041080
[TBL] [Abstract][Full Text] [Related]
10. Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs.
Bäck M; Johansson PO; Wångsell F; Thorstensson F; Kvarnström I; Ayesa S; Wähling H; Pelcman M; Jansson K; Lindström S; Wallberg H; Classon B; Rydergård C; Vrang L; Hamelink E; Hallberg A; Rosenquist S; Samuelsson B
Bioorg Med Chem; 2007 Nov; 15(22):7184-202. PubMed ID: 17845856
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of the Hepatitis C Virus NS3 protease from genotype 3a: the basis of the genotype 1b vs. 3a inhibitor potency shift.
Gallo M; Bottomley MJ; Pennestri M; Eliseo T; Paci M; Koch U; Bazzo R; Summa V; Carfì A; Cicero DO
Virology; 2010 Sep; 405(2):424-38. PubMed ID: 20630554
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
[TBL] [Abstract][Full Text] [Related]
13. Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates.
Li X; Zhang YK; Liu Y; Ding CZ; Zhou Y; Li Q; Plattner JJ; Baker SJ; Zhang S; Kazmierski WM; Wright LL; Smith GK; Grimes RM; Crosby RM; Creech KL; Carballo LH; Slater MJ; Jarvest RL; Thommes P; Hubbard JA; Convery MA; Nassau PM; McDowell W; Skarzynski TJ; Qian X; Fan D; Liao L; Ni ZJ; Pennicott LE; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Oct; 20(19):5695-700. PubMed ID: 20801653
[TBL] [Abstract][Full Text] [Related]
14. Protease and helicase activities of hepatitis C virus genotype 4, 5, and 6 NS3-NS4A proteins.
Massariol MJ; Zhao S; Marquis M; Thibeault D; White PW
Biochem Biophys Res Commun; 2010 Jan; 391(1):692-7. PubMed ID: 19944069
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans.
Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M
Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643
[TBL] [Abstract][Full Text] [Related]
16. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
Pillaiyar T; Namasivayam V; Manickam M
Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.
Raboisson P; de Kock H; Rosenquist A; Nilsson M; Salvador-Oden L; Lin TI; Roue N; Ivanov V; Wähling H; Wickström K; Hamelink E; Edlund M; Vrang L; Vendeville S; Van de Vreken W; McGowan D; Tahri A; Hu L; Boutton C; Lenz O; Delouvroy F; Pille G; Surleraux D; Wigerinck P; Samuelsson B; Simmen K
Bioorg Med Chem Lett; 2008 Sep; 18(17):4853-8. PubMed ID: 18678486
[TBL] [Abstract][Full Text] [Related]
19. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
Bowsher M; Hiebert S; Li R; Wang AX; Friborg J; Yu F; Hernandez D; Wang YK; Klei H; Rajamani R; Mosure K; Knipe JO; Meanwell NA; McPhee F; Scola PM
Bioorg Med Chem Lett; 2018 Jan; 28(1):43-48. PubMed ID: 29162454
[TBL] [Abstract][Full Text] [Related]
20. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
McCauley JA; McIntyre CJ; Rudd MT; Nguyen KT; Romano JJ; Butcher JW; Gilbert KF; Bush KJ; Holloway MK; Swestock J; Wan BL; Carroll SS; DiMuzio JM; Graham DJ; Ludmerer SW; Mao SS; Stahlhut MW; Fandozzi CM; Trainor N; Olsen DB; Vacca JP; Liverton NJ
J Med Chem; 2010 Mar; 53(6):2443-63. PubMed ID: 20163176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
